Targeting the Ghrelin Receptor as a Novel Therapeutic Option for Epilepsy

Epilepsy is a neurological disease affecting more than 50 million individuals worldwide. Notwithstanding the availability of a broad array of antiseizure drugs (ASDs), 30% of patients suffer from pharmacoresistant epilepsy. This highlights the urgent need for novel therapeutic options, preferably wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Buckinx, An, De Bundel, Dimitri, Kooijman, Ron, Smolders, Ilse
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773216/
https://www.ncbi.nlm.nih.gov/pubmed/35052733
http://dx.doi.org/10.3390/biomedicines10010053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773216/
https://www.ncbi.nlm.nih.gov/pubmed/35052733
http://dx.doi.org/10.3390/biomedicines10010053

Ejemplares similares